G6PD and tumors

Abstract

Wang Zhong, Li Zhiyu, Li Chenyuan, Sun Si, Sun Shengrong. G6PD and tumors[J]. Journal of International Oncology, 2020, 47(12): 728-731.

References34

[1]	Yang HC, Wu YH, Liu HY, et al. What has passed is prolog: new cellular and physiological roles of G6PD[J]. Free Radic Res, 2016,50(10):1047-1064. DOI: 10.1080/10715762.2016.1223296. doi:10.1080/10715762.2016.1223296pmid:27684214
[2]	Ley B, Winasti Satyagraha A, Rahmat H, et al. Performance of the access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis[J]. PLoS Med, 2019,16(12):e1002992. DOI: 10.1371/journal.pmed.1002992. doi:10.1371/journal.pmed.1002992pmid:31834890
[3]	Zhang HS, Zhang ZG, Du GY, et al. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1α/Notch1 axis[J]. J Cell Mol Med, 2019,23(5):3451-3463. DOI: 10.1111/jcmm.14241. doi:10.1111/jcmm.14241pmid:30809937
[4]	Shan C, Lu Z, Li Z, et al. 4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis[J]. Cell Death Dis, 2019,10(7):525. DOI: 10.1038/s41419-019-1756-1. doi:10.1038/s41419-019-1756-1pmid:31285420
[5]	Zhang Q, Yang Z, Han Q, et al. G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3[J]. Oncotarget, 2017,8(65):109043-109060. DOI: 10.18632/oncotarget.22566. doi:10.18632/oncotarget.22566pmid:29312589
[6]	Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydroge-nase deficiency[J]. Hematol Oncol Clin North Am, 2016,30(2):373-393. DOI: 10.1016/j.hoc.2015.11.006. doi:10.1016/j.hoc.2015.11.006pmid:27040960
[7]	Tiwari M. Glucose 6 phosphatase dehydrogenase (G6PD) and neurodegenerative disorders: mapping diagnostic and therapeutic opportunities[J]. Genes Dis, 2017,4(4):196-203. DOI: 10.1016/j.gendis.2017.09.001. doi:10.1016/j.gendis.2017.09.001pmid:30258923
[8]	Buj R, Aird KM. Deoxyribonucleotide triphosphate metabolism in cancer and metabolic disease[J]. Front Endocrinol (Lausanne), 2018,9:177. DOI: 10.3389/fendo.2018.00177. doi:10.3389/fendo.2018.00177
[9]	Chen X, Xu Z, Zhu Z, et al. Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro[J]. Int J Oncol, 2018,53(4):1703-1712. DOI: 10.3892/ijo.2018.4501. doi:10.3892/ijo.2018.4501pmid:30066842
[10]	Cui J, Pan Y, Wang J, et al. MicroRNA-206 suppresses proliferation and predicts poor prognosis of HR-HPV-positive cervical cancer cells by targeting G6PD[J]. Oncol Lett, 2018,16(5):5946-5952. DOI: 10.3892/ol.2018.9326. doi:10.3892/ol.2018.9326pmid:30344744
[11]	Liu CL, Hsu YC, Lee JJ, et al. Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells[J]. Mol Cell Endocrinol, 2020,499:110595. DOI: 10.1016/j.mce.2019.110595. doi:10.1016/j.mce.2019.110595pmid:31563469
[12]	Barajas JM, Reyes R, Guerrero MJ, et al. The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer[J]. Sci Rep, 2018,8(1):9105. DOI: 10.1038/s41598-018-27358-5. doi:10.1038/s41598-018-27358-5pmid:29904144
[13]	Tabata S, Yamamoto M, Goto H, et al. Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells[J]. Sci Rep, 2018,8(1):6760. DOI: 10.1038/s41598-018-25189-y. doi:10.1038/s41598-018-25189-ypmid:29713062
[14]	Bierhansl L, Conradi LC, Treps L, et al. Central role of metabolism in endothelial cell function and vascular disease[J]. Physiology (Bethesda), 2017,32(2):126-140. DOI: 10.1152/physiol.00031.2016.
[15]	Singh D, Arora R, Kaur P, et al. Overexpression of hypoxia-indu-cible factor and metabolic pathways: possible targets of cancer[J]. Cell Biosci, 2017,7:62. DOI: 10.1186/s13578-017-0190-2. doi:10.1186/s13578-017-0190-2pmid:29158891
[16]	李文清, 侯劲松. 上皮间质转化的表观遗传调控[J]. 国际肿瘤学杂志, 2017,44(12):918-921. DOI: 10.3760/cma.j.issn.1673-422X.2017.12.009.
[17]	Lu M, Lu L, Dong Q, et al. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition[J]. Acta Biochim Biophys Sin (Shanghai), 2018,50(4):370-380. DOI: 10.1093/abbs/gmy009. doi:10.1093/abbs/gmy009
[18]	Gandhi N, Das GM. Metabolic reprogramming in breast cancer and its therapeutic implications[J]. Cells, 2019,8(2):89. DOI: 10.3390/cells8020089. doi:10.3390/cells8020089
[19]	Haun F, Neumann S, Peintner L, et al. Identifification of a novel anoikis signalling pathway using the fungal virulence factor gliotoxin[J]. Nat Commun, 2018,9(1):3524. DOI: 10.1038/s41467-018-05850-w. doi:10.1038/s41467-018-05850-wpmid:30166526
[20]	Yang L, He Z, Yao J, et al. Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells[J]. Redox Biol, 2018,17:180-191. DOI: 10.1016/j.redox.2018.04.016. doi:10.1016/j.redox.2018.04.016pmid:29702405
[21]	Snezhkina AV, Kudryavtseva AV, Kardymon OL, et al. ROS gene-ration and antioxidant defense systems in normal and malignant cells[J]. Oxid Med Cell Longev, 2019,2019:6175804. DOI: 10.1155/2019/6175804. doi:10.1155/2019/6175804pmid:31467634
[22]	Yin X, Tang B, Li JH, et al. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway[J]. J Exp Clin Cancer Res, 2017,36(1):166. DOI: 10.1186/s13046-017-0637-7. doi:10.1186/s13046-017-0637-7pmid:29169374
[23]	Zhang R, Tao F, Ruan S, et al. The TGFβ1-FOXM1-HMGA1-TGFβ1 positive feedback loop increases the cisplatin resistance of non-small cell lung cancer by inducing G6PD expression[J]. Am J Transl Res, 2019,11(11):6860-6876. pmid:31814893
[24]	Ju HQ, Lu YX, Wu QN, et al. Disrupting G6PD-mediated redox homeostasis enhances chemosensitivity in colorectal cancer[J]. Oncogene, 2017,36(45):6282-6292. DOI: 10.1038/onc.2017.227. doi:10.1038/onc.2017.227pmid:28692052
[25]	Hong W, Cai P, Xu C, et al. Inhibition of glucose-6-phosphate dehydrogenase reverses cisplatin resistance in lung cancer cells via the Redox system[J]. Front Pharmacol, 2018,9:43. DOI: 10.3389/fphar.2018.00043. doi:10.3389/fphar.2018.00043pmid:29445340
[26]	Samatiwat P, Prawan A, Senggunprai L, et al. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents[J]. Tumour Biol, 2016,37(8):11495-11507. DOI: 10.1007/s13277-016-5015-0. doi:10.1007/s13277-016-5015-0pmid:27015836
[27]	Yang CA, Huang HY, Lin CL, et al. G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity[J]. J Neurooncol, 2018,139(3):661-670. DOI: 10.1007/s11060-018-2911-8. doi:10.1007/s11060-018-2911-8pmid:29845423
[28]	Liu B, Bai W, Ou G, et al. Cdh1-mediated metabolic switch from pentose phosphate pathway to glycolysis contributes to sevoflurane-induced neuronal apoptosis in developing brain[J]. ACS Chem Neurosci, 2019,10(5):2332-2344. DOI: 10.1021/acschemneuro.8b00644. doi:10.1021/acschemneuro.8b00644pmid:30741526
[29]	Tu D, Gao Y, Yang R, et al. The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration[J]. J Neuroinflammation, 2019,16(1):255. DOI: 10.1186/s12974-019-1659-1. doi:10.1186/s12974-019-1659-1pmid:31805953
[30]	Fang Z, Jiang C, Feng Y, et al. Effects of G6PD activity inhibition on the viability, ROS generation and mechanical properties of cervical cancer cells[J]. Biochim Biophys Acta, 2016,1863(9):2245-2254. DOI: 10.1016/j.bbamcr.2016.05.016. doi:10.1016/j.bbamcr.2016.05.016pmid:27217331
[31]	Mele L, Paino F, Papaccio F, et al. A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathwayand suppresses malignant proliferation and metastasis in vivo[J]. Cell Death Dis, 2018,9(5):572. DOI: 10.1038/s41419-018-0635-5. doi:10.1038/s41419-018-0635-5pmid:29760380
[32]	Yang HC, Wu YH, Yen WC, et al. The redox role of G6PD in cell growth, cell death,and cancer[J]. Cells, 2019,8(9):1055. DOI: 10.3390/cells8091055. doi:10.3390/cells8091055
[33]	Juliano RL. The delivery of therapeutic oligonucleotides[J]. Nucleic Acids Res, 2016,44(14):6518-6548. DOI: 10.1093/nar/gkw236. doi:10.1093/nar/gkw236pmid:27084936
[34]	Ahmad F, Dixit D, Sharma V, et al. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma[J]. Cell Death Dis, 2016,7(5):e2213. DOI: 10.1038/cddis.2016.117. doi:10.1038/cddis.2016.117

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References34

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.